NTLA Intellia Therapeutics, Inc. Stock Quote

NTLA [NASD]

Index	-	P/E	-	EPS (ttm)	-5.04	Insider Own	1.20%	Shs Outstand	74.75M	Perf Week	2.12%
Market Cap	3.70B	Forward P/E	-	EPS next Y	-5.99	Insider Trans	-0.62%	Shs Float	68.53M	Perf Month	-3.06%
Income	-368.60M	PEG	-	EPS next Q	-1.31	Inst Own	85.10%	Short Float	10.14%	Perf Quarter	-50.68%
Sales	37.90M	P/S	97.51	EPS this Y	-57.60%	Inst Trans	1.98%	Short Ratio	5.89	Perf Half Y	-56.91%
Book/sh	12.76	P/B	3.82	EPS next Y	-2.40%	ROA	-32.70%	Target Price	136.65	Perf Year	-34.95%
Cash/sh	11.28	P/C	4.32	EPS next 5Y	30.00%	ROE	-41.00%	52W Range	38.85 - 202.73	Perf YTD	-58.77%
Dividend	-	P/FCF	-	EPS past 5Y	-21.60%	ROI	-	52W High	-75.95%	Beta	2.11
Dividend %	-	Quick Ratio	6.90	Sales past 5Y	14.90%	Gross Margin	-	52W Low	25.48%	ATR	4.54
Employees	485	Current Ratio	6.90	Sales Q/Q	76.60%	Oper. Margin	-	RSI (14)	48.68	Volatility	8.34% 10.73%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-185.70%	Profit Margin	-	Rel Volume	0.83	Prev Close	45.01
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 05 BMO	Payout	-	Avg Volume	1.18M	Price	48.75
Recom	1.80	SMA20	3.90%	SMA50	-15.01%	SMA200	-53.03%	Volume	983,338	Change	8.31%

Apr-28-22

Initiated

Credit Suisse

Outperform

$100

Feb-18-22

Initiated

William Blair

Outperform

$144

Feb-07-22

Upgrade

Oppenheimer

Perform → Outperform

$145 → $150

Jan-31-22

Initiated

Cowen

Outperform

Jan-07-22

Initiated

Piper Sandler

Overweight

$171

Oct-05-21

Initiated

Guggenheim

Buy

$170

Sep-24-21

Initiated

Stifel

Buy

$173

Jun-28-21

Reiterated

H.C. Wainwright

Buy

$111 → $171

Jun-11-21

Initiated

H.C. Wainwright

Buy

$111

May-07-21

Upgrade

ROTH Capital

Neutral → Buy

$75 → $80

May-04-21

Initiated

RBC Capital Mkts

Outperform

$110

Mar-04-21

Initiated

JMP Securities

Mkt Outperform

$80

Dec-22-20

Downgrade

Robert W. Baird

Outperform → Neutral

$60

Oct-27-20

Initiated

Truist

Buy

$40

Oct-14-20

Initiated

Wells Fargo

Overweight

Sep-18-20

Initiated

Goldman

Buy

$33

Feb-28-20

Upgrade

Oppenheimer

Perform → Outperform

Feb-14-20

Downgrade

Wedbush

Outperform → Neutral

$16

Nov-01-19

Upgrade

Raymond James

Mkt Perform → Outperform

Jul-09-19

Initiated

Robert W. Baird

Outperform

$23

May-17-22 09:36AM	10 Biggest Losers in Cathie Woods Latest Portfolio Insider Monkey +5.16%
May-11-22 01:40PM	Investors might be losing patience for Intellia Therapeutics' (NASDAQ:NTLA) increasing losses, as stock sheds 14% over the past week Simply Wall St. -10.05%
May-10-22 08:26AM	Investing in These 3 Healthcare Stocks Could Double Your Money, Says Credit Suisse TipRanks +7.12%
May-06-22 03:02PM	Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat Zacks
May-05-22 08:55AM	Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates Zacks -10.18%
07:30AM	Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress GlobeNewswire
May-04-22 03:19PM	Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More Zacks +7.57%
May-03-22 08:25AM	Incyte (INCY) Lags Q1 Earnings and Revenue Estimates Zacks
May-02-22 04:01PM	Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors GlobeNewswire +5.26%
07:30AM	Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposias Precision Genome Engineering Conference GlobeNewswire
Apr-28-22 07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates GlobeNewswire
Apr-21-22 01:04PM	Serial entrepreneur Nessan Bermingham on what's next for gene editing American City Business Journals -7.90%
Apr-20-22 07:40AM	3 Top Biotech Stocks Ready for a Bull Run Motley Fool
Apr-11-22 10:12AM	Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead? Zacks
Mar-21-22 02:25PM	Cathie Woods 10 Stock Picks for the Next 5 Years Insider Monkey
Mar-17-22 09:36AM	Certara, Inc. (CERT) Soars 6.1%: Is Further Upside Left in the Stock? Zacks
Mar-11-22 12:23PM	Intellia (NTLA) Depreciates 27% Over a Month: Here's Why Zacks -7.01%
Mar-10-22 10:11AM	Intellia's (NTLA) NTLA-5001 Gets FDA Orphan Drug Tag for AML Zacks
05:29AM	Intellia's CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer Benzinga
Mar-09-22 04:01PM	Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia GlobeNewswire
12:32PM	Intellia Stock Has Tumbled. There Are Issues With Gene-Editing Patents. Barrons.com
Mar-03-22 06:29AM	Is Intellia a Good Gene-Editing Stock to Buy Now? Motley Fool -15.90%
Mar-01-22 08:00PM	Harvard, MIT Win CRISPR Patent Dispute Against Berkeley Motley Fool -19.22%
05:44PM	CRISPR ruling fallout is potentially big for UC, less so for Bay Area companies American City Business Journals
04:36PM	Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test Investor's Business Daily
02:04PM	Intellia Therapeutics Sinks as Patent Ruling Overshadows Crispr Promise Bloomberg
08:55AM	Patent Ruling Is a Setback for Gene-Editing Firms Tied to Crispr Nobelists Barrons.com
07:30AM	Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid Leukemia GlobeNewswire
06:43AM	Intellia Shares Updated Data On Gene Editing Durability In Rare Disease Benzinga
Feb-28-22 08:15PM	University of California loses breakthrough CRISPR patent in PTO ruling American City Business Journals
04:02PM	Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein PR Newswire
04:01PM	Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein GlobeNewswire
Feb-25-22 09:45AM	Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/Y Zacks +10.18%
Feb-24-22 09:15AM	Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates Zacks +9.26%
07:30AM	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress GlobeNewswire
Feb-23-22 02:45PM	Cambridge CRISPR firm inks deal for Waltham manufacturing site American City Business Journals
09:54AM	10 Genomics Stocks in Cathie Woods Portfolio That Are Underperforming Insider Monkey
08:00AM	Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies GlobeNewswire
Feb-18-22 10:02AM	Market check: Stocks mixed at open as volatility spikes Yahoo Finance Video
Feb-17-22 03:02PM	Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q4 Earnings Expected to Decline Zacks -5.70%
10:52AM	The Petri Dish: 2seventy rounds out C-suite, Moderna goes global American City Business Journals
07:30AM	Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022 GlobeNewswire
Feb-16-22 11:50AM	Intellia (NTLA) Up on Deal With ONK for Cancer Therapies Zacks
Feb-15-22 04:10PM	Intellia Therapeutics Pops After Forging A Cancer Deal Worth Nearly $1 Billion Investor's Business Daily +9.09%
07:30AM	Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer GlobeNewswire
Feb-10-22 11:55AM	Cathie Woods Ark Invest files to to launch venture fund Yahoo Finance Video
09:39AM	Newsflash: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Have Been Trimming Their Revenue Forecasts Simply Wall St.
Feb-08-22 08:08PM	Oppenheimer Says Theres Room for at Least 60% Gains in These 2 Stocks TipRanks
02:19PM	Morgan Stanley hits record as financial stocks surge, Meta shares fall, ARKK stocks slammed Yahoo Finance Video
07:03AM	Why Ark Innovation ETF stocks are getting pummeled in 2022 Yahoo Finance
Feb-05-22 01:51PM	Did Hedge Funds Catch A Break With Intellia Therapeutics, Inc. (NTLA)? Insider Monkey
Feb-04-22 10:11AM	Cathie Wood Targets Illiquid Assets and Limits Exits in New Fund Bloomberg
Feb-03-22 02:33PM	Intellia shells out up to $200M for UC Berkeley spinout American City Business Journals
07:30AM	Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics GlobeNewswire
Feb-02-22 01:38PM	Pictet & Cie (Europe) SA Buys Thermo Fisher Scientific Inc, Air Products & Chemicals ... GuruFocus.com
Jan-29-22 04:25PM	A Deep Dive Into the Video Game Industry Motley Fool
Jan-26-22 11:11AM	Seeking to separate from cell therapy pack, East Bay biotech raises $85M to target autoimmune diseases American City Business Journals
Jan-19-22 09:38PM	Aevitas Wealth Management, Inc. Buys Enbridge Inc, Mastercard Inc, Exxon Mobil Corp, Sells ARK ... GuruFocus.com
10:46AM	Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug Zacks
Jan-13-22 03:56PM	The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To These CRISPR Stocks Investor's Business Daily -8.79%
01:38PM	Marotta Asset Management Buys General Dynamics Corp, iShares iBoxx USD Investment Grade ... GuruFocus.com
06:03AM	Fresh off CRISPR milestone, Intellia lays out 2022 vision American City Business Journals
Jan-11-22 02:46PM	The Gene-Editing Industry Weighs In on Outlook at J.P. Morgan Conference Barrons.com
Jan-06-22 01:43PM	Intellia (NTLA) Inks Deal With Kyverna for Autoimmune Diseases Zacks
10:18AM	Cathie Woods flagship Ark ETF off to a rough start in 2022 down 45% from its peak Yahoo Finance
07:30AM	Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022 GlobeNewswire
Jan-05-22 04:01PM	Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 GlobeNewswire -8.97%
07:30AM	Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases GlobeNewswire
Jan-04-22 11:30AM	3 Healthcare Stocks That Could Rocket Higher in 2022 Motley Fool
Jan-03-22 06:00AM	Better Buy: CRISPR vs. Intellia Motley Fool
Dec-31-21 11:40AM	Intellia's (NTLA) CRISPR Therapies Show Promise Amid Competition Zacks
Dec-30-21 11:59AM	Cathie Wood was put to the test in 2021 and next year won't be any easier Yahoo Finance
Dec-25-21 10:38PM	Columbia Acorn Trust Buys Enphase Energy Inc, Albemarle Corp, SiteOne Landscape Supply Inc, ... GuruFocus.com
Dec-23-21 08:09AM	5 Biotech Stocks That More Than Doubled This Year Zacks
Dec-22-21 04:52PM	Top 5 Moonshots for 2022 Countdown: My No. 5 Pick InvestorPlace
Dec-20-21 07:30AM	Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer GlobeNewswire
Dec-18-21 03:38AM	Morgan Stanley Insight Fund Buys Bill.com Holdings Inc, DoorDash Inc, Datadog Inc, Sells ... GuruFocus.com
Dec-17-21 09:04AM	10 Best Genomics Stocks to Buy Now Insider Monkey +11.90%
Dec-16-21 05:38PM	Franklin Custodian Funds Buys Repligen Corp, DoorDash Inc, Intellia Therapeutics Inc, Sells ... GuruFocus.com -6.28%
09:38AM	VIP Health Care Portfolio Buys Thermo Fisher Scientific Inc, Royalty Pharma PLC, Charles River ... GuruFocus.com
Dec-14-21 11:38PM	VanEck Biotech ETF Buys Icon PLC, Bio-Techne Corp, Natera Inc, Sells , Neurocrine Biosciences ... GuruFocus.com
05:17PM	Intellia (NTLA) Begins Dosing in Hereditary Angioedema Study Zacks
Dec-13-21 07:30AM	Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema GlobeNewswire
Dec-10-21 02:02PM	3 Healthcare Stocks That Could Double Next Year Motley Fool
Dec-08-21 02:00PM	Hedge Funds Are Cashing Out Of Intellia Therapeutics, Inc. (NTLA) Insider Monkey
Nov-22-21 07:30AM	Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM) GlobeNewswire
Nov-21-21 11:31AM	Do CRISPR Therapeutics and Intellia Face a Big Safety Risk? Motley Fool
Nov-12-21 09:34AM	Intellia Therapeutics (NASDAQ:NTLA) shareholders have earned a 51% CAGR over the last five years Simply Wall St.
Nov-10-21 11:43AM	Notable Intellia Therapeutics Insider Trades $350K In Company Stock Benzinga -8.37%
10:48AM	Were These Hedge Funds Right About Piling Into Intellia Therapeutics, Inc. (NTLA)? Insider Monkey
Nov-06-21 12:30PM	Intellia Therapeutics, Inc (NTLA) Q3 2021 Earnings Call Transcript Motley Fool
Nov-05-21 07:30AM	Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-04-21 08:55AM	Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:30AM	Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress GlobeNewswire
06:20AM	Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? Zacks
Oct-28-21 03:26PM	10 Growth Stocks to Buy According to Jay Chens Himension Capital Insider Monkey +5.02%
03:05PM	Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q3 Earnings Expected to Decline Zacks
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates GlobeNewswire
Oct-22-21 10:22AM	Intellia's (NTLA) CRISPR Therapy Gets FDA's Orphan Drug Tag Zacks
Oct-21-21 07:30AM	Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis GlobeNewswire

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Goddard Glenn	EVP, Chief Financial Officer	Jan 01	Sale	112.24	1,013	113,699	2,049	Mar 03 07:38 PM
LEONARD JOHN M	President and CEO	Jan 01	Sale	112.25	2,493	279,852	724,660	Mar 04 09:07 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Jan 01	Sale	112.25	1,148	128,863	4,815	Mar 03 08:03 PM
Lebwohl David	EVP, Chief Medical Officer	Jan 01	Sale	112.24	1,051	117,964	10,922	Mar 03 08:00 PM
Lebwohl David	EVP, Chief Medical Officer	Nov 05	Option Exercise	12.62	2,400	30,288	11,114	Nov 09 06:08 PM
Lebwohl David	EVP, Chief Medical Officer	Nov 05	Sale	132.72	2,400	318,535	8,714	Nov 09 06:08 PM
Lebwohl David	EVP, Chief Medical Officer	Oct 14	Option Exercise	12.62	2,400	30,288	11,114	Oct 15 07:02 PM
Lebwohl David	EVP, Chief Medical Officer	Oct 14	Sale	128.44	2,400	308,249	8,714	Oct 15 07:02 PM
Crowley John F	Director	Oct 11	Option Exercise	18.83	2,500	47,075	4,594	Oct 13 04:15 PM
Crowley John F	Director	Oct 11	Sale	119.55	2,500	298,875	2,094	Oct 13 04:15 PM
Crowley John F	Director	Oct 05	Option Exercise	18.83	10,000	188,300	12,094	Oct 07 05:41 PM
Crowley John F	Director	Oct 05	Sale	130.54	10,000	1,305,391	2,094	Oct 07 05:41 PM
Lebwohl David	EVP, Chief Medical Officer	Sep 24	Option Exercise	12.62	7,923	99,988	8,714	Sep 27 04:15 PM
Lebwohl David	EVP, Chief Medical Officer	Sep 21	Option Exercise	12.62	2,400	30,288	3,191	Sep 23 05:48 PM
Lebwohl David	EVP, Chief Medical Officer	Sep 21	Sale	149.81	2,400	359,544	791	Sep 23 05:48 PM
Goddard Glenn	EVP, Chief Financial Officer	Sep 07	Option Exercise	14.58	3,482	50,768	3,482	Sep 09 05:38 PM
Goddard Glenn	EVP, Chief Financial Officer	Sep 07	Sale	180.12	3,482	627,178	0	Sep 09 05:38 PM
LEONARD JOHN M	President and CEO	Sep 01	Option Exercise	21.62	44,735	967,000	764,040	Sep 01 08:21 PM
LEONARD JOHN M	President and CEO	Sep 01	Sale	170.00	44,735	7,604,950	719,305	Sep 01 08:21 PM
Goddard Glenn	EVP, Chief Financial Officer	Aug 31	Option Exercise	18.93	24,800	469,374	24,800	Sep 01 07:30 PM
LEONARD JOHN M	President and CEO	Aug 31	Option Exercise	14.58	37,833	551,605	757,138	Sep 01 08:21 PM
LEONARD JOHN M	President and CEO	Aug 31	Sale	155.00	37,833	5,864,115	719,305	Sep 01 08:21 PM
Goddard Glenn	EVP, Chief Financial Officer	Aug 31	Sale	160.22	24,800	3,973,456	0	Sep 01 07:30 PM
Goddard Glenn	EVP, Chief Financial Officer	Aug 30	Option Exercise	19.27	5,200	100,204	5,200	Sep 01 07:30 PM
Lebwohl David	EVP, Chief Medical Officer	Aug 30	Option Exercise	12.62	2,400	30,288	3,191	Sep 01 07:32 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Aug 30	Option Exercise	14.01	97,000	1,359,300	99,391	Sep 01 07:34 PM
LEONARD JOHN M	President and CEO	Aug 30	Option Exercise	14.23	38,804	552,031	758,109	Sep 01 08:21 PM
LEONARD JOHN M	President and CEO	Aug 30	Sale	155.95	38,804	6,051,353	719,305	Sep 01 08:21 PM
Lebwohl David	EVP, Chief Medical Officer	Aug 30	Sale	158.04	2,400	379,300	791	Sep 01 07:32 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Aug 30	Sale	154.83	97,000	15,018,054	2,391	Sep 01 07:34 PM
Goddard Glenn	EVP, Chief Financial Officer	Aug 30	Sale	155.78	5,200	810,082	0	Sep 01 07:30 PM
LEONARD JOHN M	President and CEO	Aug 23	Option Exercise	13.40	27,139	363,663	746,444	Aug 25 04:14 PM
LEONARD JOHN M	President and CEO	Aug 23	Sale	152.01	27,139	4,125,416	719,305	Aug 25 04:14 PM
LEONARD JOHN M	President and CEO	Aug 19	Option Exercise	13.40	22,682	303,939	741,987	Aug 20 06:14 PM
LEONARD JOHN M	President and CEO	Aug 19	Sale	151.28	22,682	3,431,398	719,305	Aug 20 06:14 PM
Lebwohl David	EVP, Chief Medical Officer	Aug 09	Option Exercise	12.62	2,400	30,288	3,191	Aug 11 04:50 PM
Lebwohl David	EVP, Chief Medical Officer	Aug 09	Sale	164.05	2,400	393,720	791	Aug 11 04:50 PM
Goddard Glenn	EVP, Chief Financial Officer	Aug 05	Option Exercise	19.27	20,000	385,400	20,000	Aug 06 06:17 PM
Goddard Glenn	EVP, Chief Financial Officer	Aug 05	Sale	151.05	20,000	3,021,056	0	Aug 06 06:17 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Aug 04	Option Exercise	13.40	26,000	348,400	28,391	Aug 06 06:19 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Aug 04	Sale	138.24	26,000	3,594,357	2,391	Aug 06 06:19 PM
FORMELA JEAN FRANCOIS	Director	Jun 28	Sale	132.73	553,376	73,448,879	10,000	Jun 29 09:48 AM
FORMELA JEAN FRANCOIS	Director	Jun 14	Sale	87.37	170,779	14,921,294	563,376	Jun 15 09:51 AM
FORMELA JEAN FRANCOIS	Director	Jun 11	Sale	85.23	30,946	2,637,480	734,155	Jun 15 09:51 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience